Melanocortin Agonist · Subcutaneous

The brain is where desire starts. PT-141 starts there too.

Sildenafil and tadalafil (Viagra and Cialis) work on blood flow. They are the correct drugs for erectile dysfunction rooted in vascular problems. PT-141 works on desire itself. It targets the brain’s melanocortin system, the neurological circuitry that drives motivation, reward, and arousal, creating the foundation for sexual response before the physical response happens.

For men whose erectile dysfunction or low libido has a central or psychological component, PT-141 addresses the root mechanism that PDE5 inhibitors cannot touch. It is FDA-approved for hypoactive sexual desire disorder (HSDD) in women; off-label use in men for low libido and ED with a psychological or central component is supported by emerging evidence.

Prescription required · Free shipping
vial

PT-141 (Bremelanotide)

Clinical support for natural desire and physiological response.
Starting at
$299.00
100% Online
Board-Certified
Fast Shipping
A Different Mechanism

PT-141 and the centrally-acting pathway to sexual response.

PT-141 works through a mechanism distinct from all other ED and libido therapies. These are the facts about how it works.

2019
FDA approval yearPT-141 (bremelanotide, Vyleesi) was approved by the FDA for hypoactive sexual desire disorder (HSDD) in premenopausal women
MC3R MC4R
Target receptorsPT-141 activates melanocortin 3 and 4 receptors in the hypothalamus; distinct from all nitric oxide and vascular pathways
45-60 min
Typical onset windowPT-141 begins working within 45 to 60 minutes of injection; duration of effect is 6 to 12 hours per FDA label
1.75 mg
FDA-labeled doseThe standard subcutaneous injection dose for PT-141 is 1.75mg; not to exceed one dose per 24 hours or 8 times per month
Process

How does it work?

Step 01
phone data entry

Fill in a brief health assessment form, 100% online — takes under 10 minutes.

Step 02
clinical review

Our board-certified physicians review your answers and determine if semaglutide is appropriate for you.

Step 03
package mail

Fast, free delivery if granted a prescription — supplies included, discreet packaging, right to your door.

Clinical Applications

What patients use PT-141 for.

Hypoactive sexual desire disorder (women)FDA-Approved Use
Low sexual desire in menEmerging Research
Erectile dysfunction with psychological or central componentEmerging Research
Performance anxiety and sexual dysfunctionEmerging Research
Combination therapy with PDE5 inhibitors (Viagra, Cialis)Emerging Research
On-demand sexual enhancement (not a daily pill)Research Supported
young fitness couple running in urban area utc
Important Information

Safety & Considerations

PT-141 is a prescription medication. Your Obsidian Genetics provider will review your full health history before prescribing.

⚠ Important Safety Information

PT-141 can cause a temporary rise in blood pressure. Do not use if you are on antihypertensive medications without explicit provider clearance. Monitor blood pressure closely if you have hypertension. Avoid combined use with nitrate medications (nitroglycerin) and use extreme caution if combining with PDE5 inhibitors in men with cardiovascular disease.

Common side effects (especially during first use): nausea is the most common, reported in approximately 25–40% of users and typically transient (lasting 30 to 60 minutes). Other common effects are flushing or warmth of the face and neck, mild headache, and darkening or redness of facial skin. Most effects resolve quickly with continued use or medication adjustment. Contact your provider if side effects are persistent or concerning.

Frequently asked question

Viagra and Cialis work on blood vessels and penile tissue, increasing blood flow via nitric oxide pathway activation. PT-141 works on the brain, activating melanocortin receptors in the hypothalamus to increase sexual motivation and arousal. Viagra/Cialis address the mechanical/vascular component of ED. PT-141 addresses the desire/arousal component. They solve different problems and can be used together.

Yes. PT-141 is particularly effective for ED with a psychological, central, or low-desire component. Performance anxiety, stress, depression, and low motivation are often central nervous system issues that respond poorly to blood flow agents but respond well to melanocortin activation. PT-141 restores the neurological foundation for sexual response in these cases.

Yes, under provider supervision. Combination therapy addresses both the desire component (PT-141) and the vascular/mechanical component (PDE5 inhibitor). Many men benefit from the combined approach. Your provider assesses your cardiovascular status and adjusts dosing to minimize risk. This is a safe combination when prescribed appropriately.

Nausea is the most common side effect, reported by about 25–40% of users. It typically feels like mild queasiness or a sensation of stomach discomfort, not severe vomiting. It usually begins 20–30 minutes after injection and resolves within 30–60 minutes. Managing it: take PT-141 with food, stay hydrated, and keep the room cool. Many users find nausea decreases with subsequent injections.

PT-141 comes with an auto-injector applicator pen; injection is quick and straightforward. You inject subcutaneously on the abdomen or outer thigh. The needle is small gauge; most users report minimal to no pain. Some mild bruising or localized redness at the injection site is normal and resolves within a few hours. Your Obsidian Genetics provider demonstrates proper injection technique.

PT-141 is taken as-needed, not daily. Do not exceed one injection per 24 hours. FDA guidelines recommend no more than 8 injections per month. Many users find that PT-141 taken 1–4 times per month meets their needs. Frequency depends on your sexual activity patterns and provider recommendation. Do not self-escalate dosing without provider guidance.

Important: PT-141 (bremelanotide) as formulated here is a compounded preparation. It is not an FDA-approved drug product. Compounded medications are not reviewed by the FDA for safety, efficacy, or manufacturing standards. This product is prescribed by a licensed provider and prepared by a licensed compounding pharmacy for individual patient use. Bremelanotide (Vyleesi) is FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women only; use in men is off-label. PT-141 enhances desire and arousal through melanocortin pathway activation. It does not address testosterone deficiency directly. If your low libido or ED is rooted in hypogonadism (low testosterone), testosterone therapy or monitoring should be addressed first. PT-141 can complement testosterone therapy but does not replace it. This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before starting any new treatment. All Obsidian Genetics prescriptions are issued following a clinical review by a licensed provider. PT-141 is prescribed by licensed Obsidian Genetics providers following a clinical intake review. Your provider assesses your sexual and medical history, cardiovascular status, current medications, and goals before prescribing. PT-141 is not appropriate for everyone; your provider determines whether it is right for you.